Decreased Expression of Semaphorin 3A and Semaphorin 7A Levels and Its Association with Systemic Lupus Erythematosus

References

• Aletaha D, Neogi T, Silman AJ, et al. (2010). 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum, 62, 2569–2581. doi: 10.1002/art.27584
   PubMed Web of Science ®Google Scholar
• Apostolidis SA, Lieberman LA, Kis-Toth K, et al. (2011). The dysregulation of cytokine networks in systemic lupus erythematosus. J Interferon Cytokine Res, 31, 769–779. doi: 10.1089/jir.2011.0029
   PubMed Web of Science ®Google Scholar
• Bassyouni IH, Fawzi S, Gheita TA, et al. (2017). Clinical association of a soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in patients with systemic lupus erythematosus. Immunol Invest, 46, 38–47. doi: 10.1080/08820139.2016.1211140
   PubMed Web of Science ®Google Scholar
• Bombardier C, Gladman DD, Urowitz MB, et al. (1992). Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum, 35, 630–640.
   PubMed Web of Science ®Google Scholar
• Catalano A. (2010). The neuroimmune semaphorin-3A reduces inflammation and progression of experimental autoimmune arthritis. J Immunol, 185, 6373–6383. doi: 10.4049/jimmunol.0903527
   PubMed Web of Science ®Google Scholar
• Cervera R, Khamashta MA, Hughes GR. (2009). The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. Lupus, 18, 869–874. doi: 10.1177/0961203309106831
   PubMed Web of Science ®Google Scholar
• Costa C, Martinez-Saez E, Gutierrez-Franco A, et al. (2015). Expression of semaphorin 3A, semaphorin 7A and their receptors in multiple sclerosis lesions. Mult Scler, 21, 1632–1643. doi: 10.1177/1352458515599848
   PubMed Web of Science ®Google Scholar
• Cozacov R, Halasz K, Haj T, Vadasz Z. (2017). Semaphorin 3A: is a key player in the pathogenesis of asthma. Clin Immunol, 184, 70–72. doi: 10.1016/j.clim.2017.05.011
   PubMed Web of Science ®Google Scholar
• Czopik AK, Bynoe MS, Palm N, et al. (2006). Semaphorin 7A is a negative regulator of T cell responses. Immunity, 24, 591–600. doi: 10.1016/j.immuni.2006.03.013
   PubMed Web of Science ®Google Scholar
• Garcia-Areas R, Libreros S, Amat S, et al. (2014). Semaphorin7A promotes tumor growth and exerts a pro-angiogenic effect in macrophages of mammary tumor-bearing mice. Front Physiol, 5, 17. doi: 10.3389/fphys.2014.00268
   PubMed Web of Science ®Google Scholar
• Ghanem RC, Han KY, Rojas J, et al. (2011). Semaphorin 7A promotes angiogenesis in an experimental corneal neovascularization model. Curr Eye Res, 36, 989–996. doi: 10.3109/02713683.2011.593730
   PubMed Web of Science ®Google Scholar
• Gutierrez-Franco A, Costa C, Eixarch H, et al. (2016). Differential expression of sema3A and sema7A in a murine model of multiple sclerosis: implications for a therapeutic design. Clin Immunol, 163, 22–33. doi: 10.1016/j.clim.2015.12.005
   PubMed Web of Science ®Google Scholar
• Gutierrez-Franco A, Eixarch H, Costa C, et al. (2017). Semaphorin 7A as a potential therapeutic target for multiple sclerosis. Mol Neurobiol, 54, 4820–4831. doi: 10.1007/s12035-016-0154-2
   PubMed Web of Science ®Google Scholar
• Hochberg MC. (1997). Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 40, 1725. doi: 10.1002/1529-0131(199707)40:7<1267::AID-ART11>3.0.CO;2-L
   PubMed Web of Science ®Google Scholar
• Holmes S, Downs AM, Fosberry A, et al. (2002). Sema7A is a potent monocyte stimulator. Scand J Immunol, 56, 270–275. doi: 10.1046/j.1365-3083.2002.01129.x
   PubMed Web of Science ®Google Scholar
• Jacob N, Stohl W. (2011). Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther, 13, 228. doi: 10.1186/ar3349
   PubMed Web of Science ®Google Scholar
• Ji JD, Park-Min KH, Ivashkiv LB. (2009). Expression and function of semaphorin 3A and its receptors in human monocyte-derived macrophages. Hum Immunol, 70, 211–217. doi: 10.1016/j.humimm.2009.01.026
   PubMed Web of Science ®Google Scholar
• Kailashiya V, Singh U, Rana R, et al. (2019). Regulatory T cells and their association with serum markers and symptoms in systemic lupus erythematosus and rheumatoid arthritis. Immunol Invest, 48, 64–78. doi: 10.1080/08820139.2018.1527852
   PubMed Web of Science ®Google Scholar
• Kamata M, Tada Y, Uratsuji H, et al. (2011). Semaphorin 7A on keratinocytes induces interleukin-8 production by monocytes. J Dermatol Sci, 62, 176–182. doi: 10.1016/j.jdermsci.2011.02.004
   PubMed Web of Science ®Google Scholar
• Kang S, Okuno T, Takegahara N, et al. (2012). Intestinal epithelial cell-derived semaphorin 7A negatively regulates development of colitis via alphavbeta1 integrin. J Immunol, 188, 1108–1116. doi: 10.4049/jimmunol.1102084
   PubMed Web of Science ®Google Scholar
• Kessel A, Lin C, Vadasz Z, et al. (2017). The association between semaphorin 3A levels and gluten-free diet in patients with celiac disease. Clin Immunol, 184, 73–76. doi: 10.1016/j.clim.2017.05.010
   PubMed Web of Science ®Google Scholar
• Lepelletier Y, Moura IC, Hadj-Slimane R, et al. (2006). Immunosuppressive role of semaphorin-3A on T cell proliferation is mediated by inhibition of actin cytoskeleton reorganization. Eur J Immunol, 36, 1782–1793. doi: 10.1002/eji.200535601
   PubMed Web of Science ®Google Scholar
• Mesquita D, de Melo Cruvinel W, Araujo J, et al. (2011). Systemic lupus erythematosus exhibits a dynamic and continuum spectrum of effector/regulatory T cells. Scand J Rheumatol, 40, 41–50. doi: 10.3109/03009742.2010.489229
   PubMed Web of Science ®Google Scholar
• Micucci C, Orciari S, Catalano A. (2010). Semaphorins and their receptors in stem and cancer cells. Curr Med Chem, 17, 3462–3475.
   PubMed Web of Science ®Google Scholar
• Mine T, Harada K, Matsumoto T, et al. (2000). CDw108 expression during T-cell development. Tissue Antigens, 55, 429–436.
   PubMedGoogle Scholar
• Pan HF, Fang XH, Wu GC, et al. (2008). Anti-neutrophil cytoplasmic antibodies in new-onset systemic lupus erythematosus and lupus nephritis. Inflammation, 31, 260–265. doi: 10.1007/s10753-008-9073-3
   PubMed Web of Science ®Google Scholar
• Pan HF, Wu GC, Fan YG, et al. (2013). Decreased serum level of IL-21 in new-onset systemic lupus erythematosus patients. Rheumatol Int, 33, 2337–2342. doi: 10.1007/s00296-013-2724-1
   PubMed Web of Science ®Google Scholar
• Rezaeepoor M, Shapoori S, Ganjalikhani-Hakemi M, et al. (2017). Decreased expression of Sema3A, an immune modulator, in blood sample of multiple sclerosis patients. Gene, 610, 59–63. doi: 10.1016/j.gene.2017.02.013
   PubMed Web of Science ®Google Scholar
• Rimar D, Nov Y, Rosner I, et al. (2015). Semaphorin 3A: an immunoregulator in systemic sclerosis. Rheumatol Int, 35, 1625–1630. doi: 10.1007/s00296-015-3269-2
   PubMed Web of Science ®Google Scholar
• Stoll T, Seifert B, Isenberg DA. (1996). SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol, 35, 248–254.
   PubMedGoogle Scholar
• Suzuki K, Kumanogoh A, Kikutani H. (2008). Semaphorins and their receptors in immune cell interactions. Nat Immunol, 9, 17–23. doi: 10.1038/ni1553
   PubMed Web of Science ®Google Scholar
• Suzuki K, Okuno T, Yamamoto M, et al. (2007). Semaphorin 7A initiates T-cell-mediated inflammatory responses through alpha1beta1 integrin. Nature, 446, 680–684. doi: 10.1038/nature05652
   PubMed Web of Science ®Google Scholar
• Takagawa S, Nakamura F, Kumagai K, et al. (2013). Decreased semaphorin3A expression correlates with disease activity and histological features of rheumatoid arthritis. BMC Musculoskelet Disord, 14, 40. doi: 10.1186/1471-2474-14-40
   PubMed Web of Science ®Google Scholar
• Vadasz Z, Haj T, Halasz K, et al. (2012). Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosus. Arthritis Res Ther, 14, R146. doi: 10.1186/ar3881
   PubMed Web of Science ®Google Scholar
• Vadasz Z, Toubi E. (2014). Semaphorins: their dual role in regulating immune-mediated diseases. Clin Rev Allergy Immunol, 47, 17–25. doi: 10.1007/s12016-013-8360-4
   PubMed Web of Science ®Google Scholar
• Valencia-Pacheco G, Layseca-Espinosa E, Nino-Moreno P, et al. (2006). Expression and function of IL-10R in mononuclear cells from patients with systemic lupus erythematosus. Scand J Rheumatol, 35, 368–378. doi: 10.1080/03009740600709840
   PubMed Web of Science ®Google Scholar
• Vitali C, Bombardieri S, Jonsson R, et al. (2002). Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis, 61, 554–558. doi: 10.1136/ard.61.6.554
   PubMed Web of Science ®Google Scholar
• Xie J, Wang H. (2017). Semaphorin 7A as a potential immune regulator and promising therapeutic target in rheumatoid arthritis. Arthritis Res Ther, 19, 10. doi: 10.1186/s13075-016-1217-5
   PubMed Web of Science ®Google Scholar
• Yazdani U, Terman JR. (2006). The semaphorins. Genome Biol, 7, 211. doi: 10.1186/gb-2006-7-8-R72
   PubMed Web of Science ®Google Scholar
• Zhou Z, Tian Z, Zhang M, et al. (2018). Upregulated IL-1 receptor-associated kinase 1 (IRAK1) in systemic lupus erythematosus: IRAK1 inhibition represses Th17 differentiation with therapeutic potential. Immunol Invest, 47, 468–483. doi: 10.1080/08820139.2018.1458105
   PubMed Web of Science ®Google Scholar